Skip to main content
. 2019 Apr 10;41(6):3155–3166. doi: 10.3892/or.2019.7107

Table I.

Immunohistochemical examination of the inhibitory effect of yeast and or paclitaxel on the percentage of proliferation of EAC tumor cells in the different groups using the Ki-67 marker.

Groups Mean ± SE % of change from EAC
EAC 18.2±0.17 –
Yeast 9.1±0.31a 50
Paclitaxel-H 10.9±0.09a 40
Paclitaxel-L 11.6±0.26a 36
Yeast + Paclitaxel-H 0.7±0.058a 96
Yeast + Paclitaxel-L 0.9±0.053a 95

Data are expressed as mean ± SE of 5 mice/group.

a

P<0.01, significant difference compared to the untreated control group. EAC, Ehrlich ascites carcinoma. Groups: EAC, mice bearing tumors receiving intratumoral (i.t.) injections of PBS; Yeast, mice bearing tumors receiving i.t. injections of yeast (1×107 cells/ml); paclitaxel-H, mice bearing tumors receiving paclitaxel at a high dose (10 mg/kg); paclitaxel-L, mice bearing tumors receiving paclitaxel at a low dose (2 mg/kg); Yeast + Paclitaxel-H, mice bearing tumors receiving yeast plus paclitaxel-H; Yeast + Paclitaxel-L, mice bearing tumors receiving yeast plus paclitaxel-L.